Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

HER2 cancer vaccine - BioLife Science

Next Previous
Drug Profile

HER2 cancer vaccine - BioLife Science

Alternative Names: Her VAXX; HER-Vaxx; IMU-131; PEV 6A; PEV6

Latest Information Update: 06 Jan 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator BioLife Science; Pevion Biotech
  • Developer Imugene; Pevion Biotech
  • Class Antineoplastics; Cancer vaccines; Immunotherapies; Peptide vaccines
  • Mechanism of Action ERBB 2 receptor antagonists; Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Adenocarcinoma; Gastric cancer
  • Phase I/II Oesophageal cancer
  • No development reported Breast cancer

Most Recent Events

  • 13 Sep 2024 Updated efficacy data from a phase I/II HERIZON trial in Gastric cancer presented at the49th European Society for Medical Oncology Congress (ESMO-2024)
  • 05 Apr 2024 Final efficacy and immunogenicity data from the phase-I/II HERIZON trial in Gastric cancer and Oesophageal cancer presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)
  • 04 Apr 2024 Imugene Limited completes a phase-II trials in Gastric cancer and Adenocarcinoma (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in Taiwan and Australia (IM) (NCT05311176)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top